Project Grant R01CA300566
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $544K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Princeton, NJ, USA
Similar Awards
- Federal Grant Award Summary Princeton University's Office of Research and Project Administration received a $451,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective April 1, 2026 through January 31, 2031. The award supports discovery and application of new enzymes for amino acid and peptide modification, with research performed at Princeton's facilities in Princeton, New Jersey. The...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $692,197 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2031. The award funds research and development of MTAP (Methylthioadenosine Phosphorylase) transition state analog inhibitors designed to enable synthetic-lethal cancer therapy approaches. The project delivers novel, highly specific MTAP inhibitor compounds and...
- Federal Grant Award Summary Temple University received a $177,209 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on July 18, 2025, with a completion date of June 30, 2027. The award supports research aimed at developing fluorine-thiol displacement reaction (FTDR)-stapled peptide probes to target C-MYC, an undruggable transcription factor implicated in castration-resistant prostate cancer (CRPC) progression. The research...
- Federal Grant Award Summary Princeton University received a $151,352 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded June 26, 2026, with a completion date of June 25, 2027. The award supports fundamental research into stereoselective photoenzymatic transformations mediated by pyridoxal 5'-phosphate (PLP) cofactors, with research to be conducted at the university's Princeton, New...
- Federal Grant Award Summary The National Cancer Institute awarded a $122,610 Project Grant to the University of Pennsylvania on August 11, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award, with a completion date of July 31, 2030, supports the development of a system to advance National Cancer Institute (NCI)-sponsored clinical trials for patients with rare gastrointestinal malignancies and rare disease populations. The project leverages the principal investigator's...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded the Regents of the University of Michigan a $2.86 million Project Grant on September 10, 2025, with a completion date of August 31, 2029. This research initiative develops novel therapeutic strategies to combat colibactin, a carcinogenic metabolite produced by pathogenic enteric bacteria associated with colorectal cancer (CRC). The project delivers two primary products: (1) an...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $151,920 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This award supports fundamental research to develop and validate Nuclear Magnetic Resonance (NMR) strategies for investigating allosteric inhibitor binding effects on Src-family kinases implicated in acute myeloid leukemia (AML). The research aims to characterize...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Biology Research program (CFDA 93.396), awarded a $661,721 Project Grant to the University of California, San Diego, with an award date of April 1, 2026, and a completion date of March 31, 2031. This five-year research initiative focuses on systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The project will utilize novel high-throughput...